BUZZ-Invivyd rises as drugmaker starts late-stage trial for COVID prevention antibody
I'm PortAI, I can summarize articles.
Shares of drugmaker Invivydrise 1.4% to $2.92 premarketCo says it has started late-stage clinical trial to test its experimental COVID-19 antibody, VYD2311, as a preventive treatment for the diseaseStudy will enroll 1,770 adults and teens; compare single vs monthly shots to placebo, says coIVVD says the goal is to offer vaccine alternative for high-risk people seeking protectionTop-line results expected by mid-2026 - IVVDUp to last close, stock up ~133% YTD
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments